Abstract
The need to identify disease biomarkers is critical to ensure fast diagnosis and timely treatment. Surface enhanced laser desorption/ionization time-of-fight mass spectrometry (SELDI-TOF-MS) is a widely used technology platform for diagnostic biomarker discovery. This short review provides an overview of how it functions and also describes its advantages and drawbacks.
Keywords: Surface enhanced laser desorption/ionization, proteomics, biomarker, liver diseases
Protein & Peptide Letters
Title: SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease
Volume: 16 Issue: 5
Author(s): Lei Chen, Sarwat Fatima, Jirun Peng and Xisheng Leng
Affiliation:
Keywords: Surface enhanced laser desorption/ionization, proteomics, biomarker, liver diseases
Abstract: The need to identify disease biomarkers is critical to ensure fast diagnosis and timely treatment. Surface enhanced laser desorption/ionization time-of-fight mass spectrometry (SELDI-TOF-MS) is a widely used technology platform for diagnostic biomarker discovery. This short review provides an overview of how it functions and also describes its advantages and drawbacks.
Export Options
About this article
Cite this article as:
Chen Lei, Fatima Sarwat, Peng Jirun and Leng Xisheng, SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease, Protein & Peptide Letters 2009; 16 (5) . https://dx.doi.org/10.2174/092986609788167851
DOI https://dx.doi.org/10.2174/092986609788167851 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Quantum Dots in the Therapy: Current Trends and Perspectives
Mini-Reviews in Medicinal Chemistry Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets
Current Medicinal Chemistry Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Determination of Dysregulated miRNA Expression Levels by qRT-PCR after the Application of Usnic Acid to Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Heterocycles in the Treatment of Neglected Tropical Diseases
Current Medicinal Chemistry Diselenides and Selenocyanates as Versatile Precursors for the Synthesis of Pharmaceutically Relevant Compounds
Current Organic Synthesis Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy
Current Drug Targets Multiple Target-Specific Molecular Imaging Agents Detect Liver Cancer in a Preclinical Model
Current Molecular Medicine Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology Meet Our Editorial Board Member:
Current Pharmaceutical Design Tumoral Drug Metabolism: Perspectives and Therapeutic Implications
Current Drug Metabolism In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry The Anticancer Activity of the N-Terminal CARD-Like Domain of Arginine Deiminase (ADI) from Pseudomonas aeruginosa
Letters in Drug Design & Discovery Local Gene Delivery for Cancer Therapy
Current Gene Therapy Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy
Current Cancer Drug Targets Membrane Interacting Peptides: A Review
Current Protein & Peptide Science Review: Alternative Splicing (AS) of Genes As An Approach for Generating Protein Complexity
Current Genomics Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery